Loading stock data…
GPCR
$42.21+0.76 (+1.83%)
Pre-Market$42.22+0.01 (+0.02%)· Last close May 1
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Structure Therapeutics Inc. in the Healthcare sector is trading at $42.21. The stock is currently 56% below its 52-week high of $94.90, remaining 5.5% below its 200-day moving average. Technical signals show oversold RSI of 14 and bearish MACD signal, explaining why GPCR maintains its current current market pressure. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 14) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$42.21
Potential Upside
5%
Whystock Fair Value$44.32
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus16 analysts
Mean target$108.50+157.0%
Range$90.00 – $145.00
Fundamentals
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate i...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.26B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-1.25
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-0.00%
Volume
Today's trading volume
1.35M
Recent News
Why Structure Therapeutics (GPCR) Is Down 7.2% After Strong Oral GLP-1 Phase 2 Data And FDA Plans
Structure Therapeutics recently reported encouraging Phase 2 ACCESS II trial results for its oral GLP-1 receptor agonist aleniglipron, showing up to 16.3% weight reduction in adults with obesity and outlining plans for an end-of-Phase 2 FDA meeting in the second quarter of 2026 ahead of Phase 3 trials later in the year. The data position aleniglipron as one of the most effective oral GLP-1 candidates in terms of weight loss, potentially reshaping how investors view oral obesity treatments...
Here is Why Structure Therapeutics (GPCR) is One of the Top Biotech Names to Look at
Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the 10 best biotech stocks with highest upside potential. As of April 24 closing, the stock carries a strongly bullish consensus sentiment, receiving Buy ratings from all 14 analysts. Based on a 1-year median target price of $107.77, it currently offers an upside potential of almost 138%. Back […]
LLY's Oral GLP-1 Pill Foundayo Shows Heart Benefits in Diabetes Study
LLY's oral GLP-1 pill Foundayo shows cardiovascular benefits, weight loss, and strong glucose lowering in a phase III study as the FDA seeks more safety data.
3 Ways to Invest in the Growing GLP-1 Weight Loss Market
GLP-1 drugs are big business, and investors can win rewards by searching beyond the biggest names or diversifying via ETFs.
LLY Stock Down as FDA Asks for More Safety Data on Oral Obesity Pill
LLY stock slips after FDA seeks added safety data on its new oral obesity pill Foundayo, raising questions despite blockbuster sales hopes.